Antiplatelet agent resistance and prevention and treatment of stroke
10.3760/cma.j.issn.1673-4165.2013.05.009
- VernacularTitle:抗血小板药抵抗与卒中防治
- Author:
Zhao YANG
;
Jianrong LIU
- Publication Type:Journal Article
- Keywords:
Platelet Aggregation Inhibitors;
Drug Resistance;
Stroke;
Aspirin;
Clopidogrel
- From:
International Journal of Cerebrovascular Diseases
2013;21(5):378-384
- CountryChina
- Language:Chinese
-
Abstract:
A large number of studies have confirmed that antiplatelet agents reduce the relative risk of stroke,myocardial infarction,or death by an average of 22％.However,many patients still have thrombotic events during the period of taking anti-platelet agents,and this is called anti-platelet agent resistance.Its incidences reported are very different.The incidence of aspirin is 3％ to 85％,and that of clopidogrel is 28％ to 44％.The exact cause of antiplatelet agent resistance remains unclear.It may be associated with several factors,including decreased drug bioavailability,genetic polymorphisms,activation of other platelet activation pathways,and increased circulating platelets.Currently,a variety of laboratory methods have been used to detect antiplatelet agent resistance,its criteria are different.In addition,the response measures of antiplatelet agent resistance also have no conclusion,and this has brought greater difficulties for the prevention and treatment of stroke.
